BeyondSpring Inc.
AI Valuation
AI-generated fair value estimate for this company.
AI Fair Value
$0.45
Market Price
$0.61
Overvalued By
35.3%
Method: Risk-adjusted net-asset approach: $6.53M net cash (cash+ST investments minus debt) divided by 41.12M shares = $0.159/share cash floor, plus a modest pipeline option premium (~180% of cash floor) for Plinabulin Phase III NSCLC data and FDA Fast Track designation; no revenue or FCF exists to discount.
Reasoning: BeyondSpring is a pre-revenue clinical-stage biopharma; a standard FCF DCF is not meaningful with zero revenue and continuous cash burn, so value is anchored to net cash with a limited option-value add-on for the de-risked (Phase III, Fast Track) lead asset, reflecting binary trial/regulatory risk and a thin cash runway.